Bromfenac Sodium
Bromfenac Sodium structure
|
Common Name | Bromfenac Sodium | ||
|---|---|---|---|---|
| CAS Number | 91714-93-1 | Molecular Weight | 356.147 | |
| Density | N/A | Boiling Point | 562.2ºC at 760 mmHg | |
| Molecular Formula | C15H11BrNNaO3 | Melting Point | 285ºC | |
| MSDS | Chinese USA | Flash Point | 293.8ºC | |
| Symbol |
GHS09 |
Signal Word | Warning | |
|
Multiparametric assay using HepaRG cells for predicting drug-induced liver injury.
Toxicol. Lett. 236 , 16-24, (2015) The utility of HepaRG cells as an in vitro cell-based assay system for assessing drug-induced liver injury (DILI) risk was investigated. Seventeen DILI-positive and 15 DILI-negative drugs were selected for the assay. HepaRG cells were treated with each drug f... |
|
|
Efficacy of ophthalmic nonsteroidal antiinflammatory drugs in suppressing anterior capsule contraction and secondary posterior capsule opacification.
J. Cataract Refract. Surg. 35(9) , 1614-8, (2009) To evaluate the efficacy of ophthalmic nonsteroidal and steroidal antiinflammatory drugs in preventing anterior capsule contraction and secondary posterior capsule opacification (PCO) using an experimental cataract model.Department of Ophthalmology, Dokkyo Me... |
|
|
Cyclooxygenase (COX)-inhibiting drug reduces HSV-1 reactivation in the mouse eye model.
Curr. Eye Res. 34(3) , 171-6, (2009) To examine the effects of COX inhibitors on suppressing HSV-1 reactivation in a mouse model.BALB/c mice were latently infected with HSV-1 and treated by 0.1% bromfenac Na eye drops, 0.1% pranoprofen eye drops, 0.1 mg oral etodolac 4 times/day, and saline for ... |
|
|
Aqueous prostaglandin E(2) of cataract patients at trough ketorolac and bromfenac levels after 2 days dosing.
Adv. Ther. 26(6) , 645-50, (2009) Ketorolac 0.4% administered four times daily (q.i.d.) has long been used safely and effectively for the alleviation of ocular inflamation and pain and the prevention of intraoperative miosis in patients undergoing cataract surgery. Bromfenac ophthalmic soluti... |
|
|
Comparison of efficacy of bromfenac sodium 0.1% ophthalmic solution and fluorometholone 0.02% ophthalmic suspension for the treatment of allergic conjunctivitis.
J. Ocul. Pharmacol. Ther. 25(3) , 265-70, (2009) Bromfenac sodium (BF) 0.1% was compared with fluorometholone (FML) 0.02% for the treatment of seasonal allergic conjunctivitis when concomitantly used with disodium cromoglycate (DSCG) 2.0%.Eighty-six patients with seasonal allergic conjunctivitis were treate... |
|
|
Acute corneal melt associated with topical bromfenac use.
Eye Contact Lens 38(4) , 260-2, (2012) To report a case of acute corneal melt associated with use of bromfenac ophthalmic solution.Case report.A 61-year-old man developed acute corneal melt 5 days after having combined cataract and pterygium surgery in his left eye. Postoperatively, he had been us... |
|
|
Ocular penetration and anti-inflammatory activity of ketorolac 0.45% and bromfenac 0.09% against lipopolysaccharide-induced inflammation.
J. Ocul. Pharmacol. Ther. 27(2) , 173-8, (2011) Anti-inflammatory activity of topical nonsteroidal anti-inflammatory drugs is mediated by suppression of cyclooxygenase (COX) isoenzymes. This study compared ocular penetration and inflammation suppression of topical ketorolac 0.45% and bromfenac 0.09% ophtha... |
|
|
Pharmacokinetic comparisons of bromfenac in DuraSite and Xibrom.
J. Ocul. Pharmacol. Ther. 27(1) , 61-6, (2011) The purpose of this study was to compare the ocular pharmacokinetics of experimental solutions of bromfenac in DuraSite(®) to Xibrom™ (bromfenac ophthalmic solution) 0.09%.The bromfenac content was measured in the aqueous humor of 84 Dutch Belted rabbits afte... |
|
|
Efficacy and safety of bromfenac for the treatment of corneal ulcer pain.
Adv. Ther. 27(10) , 756-61, (2010) To evaluate the efficacy and safety of bromfenac ophthalmic solution 0.09% (Xibrom™, ISTA Pharmaceuticals Inc., Irvine, CA, USA) for treating pain associated with corneal ulcers.Twenty-five eyes of 24 patients with corneal infiltrates (bacterial or fungal) we... |
|
|
Ophthalmic utility of topical bromfenac, a twice-daily nonsteroidal anti-inflammatory agent.
Expert Opin. Pharmacother. 10(14) , 2379-85, (2009) Topical nonsteroidal anti-inflammatory drugs (NSAIDs) act by inhibiting the formation of prostaglandin by cyclooxygenases. Several agents in this class have been approved for the treatment of postoperative pain and inflammation following cataract surgery. Bro... |